APOA1 and myocardial infarction: This is the first known variant of apoA-I in which heterozygous carriers have an increased risk of ischemic heart disease (IHD), myocardial infarction (MI) and mortality whilst showing no difference in HDL cholesterol levels, plasma lipids or apoA-I concentration compared to noncarriers [9].